sglt2 inhibitors vs glp 1 agonists Effect of combination treatment with glucagon-like peptide-1 receptor and sodium-glucose cotransporter-2 on incidence of cardiovascular and serious renal events: population based cohort study Perioperative GLP-1/GIP & SGLT2 Inhibitors
Description
market was valued at $9.5 billion in 2024 and is expected to expand to $47.53 billion by 2030 , reflecting a 30.8% CAGR
Additionally, GLP-1RAs ameliorate DPN through various mechanisms, including the inhibition of inflammation, oxidative stress, and extracellular matrix remodeling, while simultaneously improving neural structure, function, and energy metabolism [11, 12, 30, 79,80,81,82,83,84,85,86]
doi: 10.1136/bmjdrc-2020-001649 [DOI] [PMC free article] [PubMed] [Google Scholar] 43
It ushered in a whole new class of diabetes medications that are arguably safer, and more effective, than previous treatments were
For six decades, we have inspired millions of people to adopt healthy habits for real life
2000;284:301521 [17] Fildes A, Charlton J, Rudisill C, Littlejohns P, Prevost AT, Gulliford MC
